• 제목/요약/키워드: adverse effect

검색결과 2,286건 처리시간 0.036초

비만처방에서의 안전한 마황사용 지침 (The Safety Guidelines for use of Ma-huang in Obesity Treatment)

  • 송미영;김호준;이명종
    • 한방비만학회지
    • /
    • 제6권2호
    • /
    • pp.17-27
    • /
    • 2006
  • Objectives : Ma-huang (Ephedra sinica) is frequently prescribed for obesity management in oriental medicine. The main component is ephedrine alkaloids which can have serious adverse side effects such as heart attack, stroke, sudden death. There are no scientific guidelines for Ma-huang usage in the safe treatment of obesity in oriental medicine. We reviewed published studies on its safety to make evidence based guidelines. Methods : We searched electronic databases up to May 2006. We limited evidence to controlled trials for efficacy or safety, case reports for safety, and studies for Ma-huang contents analysis. Results and Conclusions : In clinical trials for weight loss, Ma-huang and ephedrine promote modest short-term weight loss but have no serious adverse effects, have only a few adverse effects associated with increased risk of psychiatric, autonomic, gastrointestinal symptoms and heart palpitations. In case reports, there have been serious adverse effects including stroke, heart attack, and death using typical doses of ephedrine or no associated illness. There are factors related to serious adverse effects, such as overuse, lack of standardization, individual sensitivity, and interactions with other drugs. Studies relating to these factors should be analyzed for safe use of Ma-huang and ephedrine. After analyzing related studies, we suggest guidelines for Ma-huang usage. We propose that the dosage should be within 4.5-7.5g per day for up to 6 months for generally healthy individual. It's use is contraindicated in individuals with heart disease, thyroid disease, diabetes mellitus, hypertension, psychiatric disorders, glaucoma, urination disorders, enlarged prostate, persons using MAOIs, methyldopa and sympathomimetic agents.

  • PDF

청소년의 고카페인 에너지음료 섭취 실태 및 부작용 경험 (Consumption Status and Experience of Adverse Effects of High-caffeine Energy Drink among High School Students)

  • 오윤정
    • 융합정보논문지
    • /
    • 제9권6호
    • /
    • pp.35-43
    • /
    • 2019
  • 본 연구는 고등학생의 고카페인 에너지음료 섭취 실태와 부작용 경험을 파악하기 위한 실시된 조사연구이다. 수집된 245명의 자료를 SPSS 18로 기술통계와 ${\chi}^2-test$를 실시하였다. 본 연구대상자의 79.5%가 고카페인 에너지음료를 마신 경험이 있었다. 고카페인 에너지음료 섭취 후 50.6%가 부작용을 경험했으며, 부작용 중 가슴 두근거림이 가장 많았다. 일반적인 특성 중 한 달 용돈(p=.019)과 음주 여부(p=.033)에 따라 고카페인 에너지음료 섭취 경험과 유의한 차이가 있었고, 성별(p=.001)과 건강상태(p=.006)에 따라 부작용 경험과 유의한 차이가 있었다. 또한 고카페인 에너지음료 섭취 실태에 따른 부작용 경험과의 차이는 고카페인 에너지음료의 섭취 이유(p=.040)와 섭취 시기(p=.005)에 따라 유의한 차이가 있었다. 고등학생들의 고카페인 에너지음료의 소비를 줄이기 위해서는 고카페인 음료의 판매를 제한할 수 있는 정책적인 방안이 마련되어야 할 것이며, 학생 스스로가 조절할 수 있는 역량 함양을 위해 지속적인 건강교육이 필요할 것이다.

유비쿼터스 서비스의 역기능 분석 및 방지를 위한 제언 (A Proposal on Analyzing and Preventing Adverse Effects of Ubiquitous Services)

  • 강민철;곽수환;김창수
    • 한국정보시스템학회지:정보시스템연구
    • /
    • 제19권4호
    • /
    • pp.87-109
    • /
    • 2010
  • The ubiquitous computing & technology is to make passive IT machinery as the smart-object to solve the problems of information management. These ubiquitous devices can be a concierge of humans lives. In addition, the ubiquitous computing & technology added with Pro-Active processing technology is the intellectual automatic process capacity that probably enhance quality of human's life. Although the social influencing power of ubiquitous computing technology is so critical, research on the social impact of ubiquitous has been studied insufficiently. And, we also need the countermeasures to protect the societies from the side effect of the ubiquitous computing technology. The purpose of this research is to minimize the loss which comes from the new ubiquitous society, by presenting the technological and systematic alternatives and by researching the various side effects. This research suggests the proper alternatives by reviewing and by researching the adverse effects of the ubiquitous computing technology.

In Silico Prediction of Organ Level Toxicity: Linking Chemistry to Adverse Effects

  • Cronin, Mark T.D.;Enoch, Steven J.;Mellor, Claire L.;Przybylak, Katarzyna R.;Richarz, Andrea-Nicole;Madden, Judith C.
    • Toxicological Research
    • /
    • 제33권3호
    • /
    • pp.173-182
    • /
    • 2017
  • In silico methods to predict toxicity include the use of (Quantitative) Structure-Activity Relationships ((Q)SARs) as well as grouping (category formation) allowing for read-across. A challenging area for in silico modelling is the prediction of chronic toxicity and the No Observed (Adverse) Effect Level (NO(A)EL) in particular. A proposed solution to the prediction of chronic toxicity is to consider organ level effects, as opposed to modelling the NO(A)EL itself. This review has focussed on the use of structural alerts to identify potential liver toxicants. In silico profilers, or groups of structural alerts, have been developed based on mechanisms of action and informed by current knowledge of Adverse Outcome Pathways. These profilers are robust and can be coded computationally to allow for prediction. However, they do not cover all mechanisms or modes of liver toxicity and recommendations for the improvement of these approaches are given.

청혈단(淸血丹)의 임상적인 부작용에 대한 연구 (Clinical Assessment on the Safety of Chunghyul-dan (Qingwie-dan))

  • 조기호;정우상;박성욱;문상관;김영석;배형섭
    • 대한한의학회지
    • /
    • 제24권3호
    • /
    • pp.45-50
    • /
    • 2003
  • Background and Purpose : Chunghyul-dan has been widely used in the Department of Cardiovascular & Neurologic Diseases, Kyung Hee Oriental Medical Center to prevent stroke by lowering serum cholesterol level. Previous experimental and clinical studies revealed that Chunghyul-dan had therapeutic effects on hyperlipidemia by inhibiting HMG-CoA reductase and pancreatic lipase. It was also reported that Chunghyul-dan showed an anti-oxidation effect by scavenging free radicals and inhibiting nitric oxide synthesis. Therefore, we examined the safety of Chunghyul-dan on all subjects who had been treated with it. Methods : We performed a retrospective study by reviewing the medical records of those who had been administrated Chunghyul-dan at Kyung Hee Oriental Medical Center from February 8,2001 to December 31,2002. The subjects' general characteristics (gender, age, medical history, and present illness), recorded adverse effects, and the results of laboratory findings were obtained and analyzed to assess the clinical safety of Chunghyul-dan. Results : Six hundred fifty six subjects were treated with Chunghyul-dan. Clinical adverse effects appeared in 13 subjects, the major symptom being indigestion (8 subjects). The apparent frequency of adverse effects was much lower than that in previous reports on the safety of certain medications. On investigation of laboratory findings, we could not find any hepatic or renal toxicity. Conclusion : We suggest that our results contribute towards confirming the safety of Chunghyul-dan by offering clinical evidence.

  • PDF

신생아에서 Chloral Hydrate의 부작용의 빈도와 관련 인자 (Adverse Effects of Chloral Hydrate in Neonates: Frequency and Related Factors)

  • 이주영;윤영아;김순주;이현승;김소영;성인경;전정식
    • Neonatal Medicine
    • /
    • 제18권1호
    • /
    • pp.130-136
    • /
    • 2011
  • 목적: Chloral hydrate는 검사 시 진정 목적으로 흔히 사용하는 약물이나 신생아에 관해서는 충분한 연구가 이루어지지 않고 있다. 이에 저자들은 신생아중환자실에서 chloral hydrate의 사용 시에 나타나는 부작용의 빈도와 그에 영향을 미치는 요소에 대해 알아보고자 한다. 또한 chloral hydrate만으로 진정이 되지 않아 추가 약물을 투여하는 경우 부작용이 증가하는지에 관해 알아보고자 한다. 방법: 2010년 3월부터 2011년 2월까지 가톨릭대학교 서울성모병원 신생아중환자실에서 검사 시 진정 목적으로 chloral hydrate를 사용한 104명을 대상으로 의무기록을 후향적으로 조사하였다. 결과: Chloral hydrate 투여 시 부작용은 41.3%에서 나타났으며 산소 포화도 감소(18.8%), 무호흡 증가(17.5%), 서맥 증가(10%), 수유량 감소(3.8%)가 있었다. Chloral hydrate 투여 시부작용은 chloral hydrate 투여 시기에 산소 투여 여부와 관련이 있었다(odds ratio [OR], 10.911: 95% confidence interval [CI], 2.082-57.178). 추가 약물 투여는 chloral hydrate 투여 시 산소 투여 여부와 관련이 있었고(OR, 4.151: 95% CI, 1.455-11.840) chloral hydrate 단독 투여 군에 비해 수유량 감소를 제외하고는 부작용에 유의한 차이가 없었다. 결론: 진정 요법이 필요한 검사 시 산소를 투여하고 있는 신생아에서 chloral hydrate의 사용은 부작용이 나타날 가능성이 높고 추가 약물 투여의 가능성이 높다. 추가 약물 투여가 필요한 경우에는 진정 유도 후 나타나는 수유량 감소에 주의하면서 진정을 유도할 수 있겠다.

A prospective study to assess the efficacy and safety of oral propranolol as first-line treatment for infantile superficial hemangioma

  • Yun, Yeong Ju;Gyon, Yun Hee;Yang, Sohyoung;Lee, Youn Kyung;Park, Joohyun;Park, Meerim
    • Clinical and Experimental Pediatrics
    • /
    • 제58권12호
    • /
    • pp.484-490
    • /
    • 2015
  • Purpose: To determine the efficacy and safety of oral propranolol as a first-line treatment for superficially located infantile hemangioma (IH) and propose an assessment tool to measure treatment response. Methods: Patients with superficial IH under 1 year of age were prospectively recruited between May 2012 and December 2013 at the Department of Pediatrics of Chungbuk National University Hospital. Propranolol was administered to 12 infants (median age, 3.8 months) while monitoring cardiovascular and adverse metabolic effects. If a patient showed no adverse events, the dosage was gradually increased up to 3 mg/kg/day and maintained for 1 year. We used our own scoring system to assess treatment response using parameters like change in color, and longest diameter, and thickness of the IH. Results: Eleven out of 12 patients completed the protocol with consistent improvement of hemangiomas during therapy. Patients on propranolol showed a more than 50% involution in the first 3 months, with additional steady involution until 1 year. Patients with the highest scores at 1 month maintained their score and showed better responses until treatment termination. The patient with the lowest score at 1 month did not show any further regression and stopped propranolol treatment 4 months after initiation. In two children with recurrences after successful therapeutic regression, propranolol was effective after being reintroduced. Propranolol treatment was not interrupted in any patient due to adverse events. Conclusion: Oral propranolol at 3 mg/kg/day showed a consistent, rapid, and therapeutic effect on superficial IHs without significant adverse events.

미국 식품의약국 미승인 두타스테라이드의 국내 남성형 탈모증 약물요법 적용에대한 후향적 평가 (Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea)

  • 천영주;김정태;임성실
    • 한국임상약학회지
    • /
    • 제25권3호
    • /
    • pp.171-177
    • /
    • 2015
  • Background: Androgenetic alopecia (AGA), one of alopecias, requires continuous treatment in order to prevent or stop it, and patient's compliance is very important. Currently, only two drugs (finasteride, minoxidil) have been approved for AGA by Food and Drug Administration of United States (US FDA). However, another ${\alpha}-2$ reductase inhibitor, dutasteride, is approved by Korea Ministry of Food and Drug Safety (MFDS) through a phase III trial. For treatment, pharmacotherapy of AGA usually combines topical minoxidil 7% with one of oral <${\alpha}-2$ reductase inhibitor. Objectives: We evaluated the comparative efficacy and adverse effect between topical minoxidil 7%/finasteride 1 mg and topical minoxidil 7%/dutasteride 0.5 mg pharmacotherapy for outpatients with AGA. Also we evaluated the relationship between therapeutic effect and regular hospital visit. Method: This study was performed retrospectively based on electronic medical record (EMR) data of total 98 patients (topical minoxidil 7% with dutasteride 0.5 mg ($Avodart^{(R)}$) or finasteride 1 mg ($Alopecia^{(R)}$, $Propecia^{(R)}$) with diagnosis of AGA from department of dermatology at a secondary hospital from January $1^{st}$, to May $31^{st}$, 2014. Results: The efficacy and adverse event of topical minoxidil 7%/dutasteride 0.5 mg (DUTA group) were 100% and 45.7%, and of topical minoxidil 7%/finasteride 1 mg (FINA group) were 92.1% and 33.3%, respectively. The mean onset time of responses and adverse events in the FINA group were 3.86 months and 4.43 months. Those in the DUTA group were 3.97 months and 5.06 months. Conclusion: Both FINA and DUTA group were highly effective, but the DUTA group showed higher efficacy and adverse effects than those in the FINA group. Dutasteride may be another alternative in AGA treatment.

급성 중독 환자에서 지질 유탁액 정맥투여의 효과: 체계적 고찰 (Effect of Intravenous Lipid Emulsion in the Patient with Acute Poisoning : A Systematic Review)

  • 명진우;고동률;공태영;주영선;유제성;정성필
    • 대한임상독성학회지
    • /
    • 제13권1호
    • /
    • pp.1-10
    • /
    • 2015
  • Purpose: The purpose of this study was to evaluate the usefulness of intravenous lipid emulsion as well as adverse events in acute poisoning patients. Methods: Literature was accessed through PubMed, EMBASE, Cochrane library, Web of science, and KoreaMed. All forms of literatures relevant to human use of intravenous lipid emulsion for acute poisoning were included. Cases reports or letters without description of clinical outcomes for each case were excluded. The literature search was conducted by two investigators in March, 2015, with publication language restricted to English and Korean. The effect, onset time, and adverse event of lipid emulsion and final outcome of each case were analyzed. Results: Eighty-one published articles were included, excluding articles whose title and abstract were not relevant to this study. No articles were classified as high level of evidence. Sixty-eight case reports were identified, consisting of 25 local anesthetics and 43 other drugs, such as tricyclic antidepressants and calcium channel blockers. Although most cases described significant clinical improvements, some of them showed no beneficial effect or worsening of clinical course. Several adverse events including hyperamylasemia and laboratory interference were reported. Conclusion: Although there were many case reports illustrating successful use of lipid for various drug poisonings, the effect cannot be estimated due to significant possibility of publication bias. Therefore, lipids might be considered in severe hemodynamic instability resulting from lipophilic drug poisoning, however further studies should follow to establish the use of lipid as the standard of care.

  • PDF

ICR 마우스에서 핑크왐피 추출물의 3주간 반복 투여 독성 연구 (3-week repeated dose oral toxicity study of Clausena excavata extract in ICR mice)

  • 박주형;조영락;김영민;강재신;오좌섭;안은경
    • Journal of Applied Biological Chemistry
    • /
    • 제62권2호
    • /
    • pp.123-127
    • /
    • 2019
  • 핑크왐피는 피부병, 말라리아, 복통, 이질 및 장염 치료를 위한 약용 식물로 사용되고 있다. 본 연구의 목적은 핑크왐피의 안전성을 확인하기 위하여, 수컷 ICR 마우스를 이용하여 핑크왐피를 3주 반복 경구 투여하여 최대무독성용량을 평가했다. 핑크왐피를 100, 250, 500, 1000, 및 2000 mg/kg으로 투여한 결과, 모든 시험물질 투여군에서 이상이 관찰되지 않았다. 사망률, 임상 증상, 체중 변화, 혈액 학적 검사 및 혈청 생화학 검사에서 유의적인 차이는 없었고, 경미한 변동은 핑크왐피의 투여로 인한 영향이 아닌 정상 범위 내에서의 변화로 간주 되어진다. 결과적으로, 핑크왐피는 모든 시험물질 투여군에서 독성 영향을 미치지 않았으며, 핑크왐피의 최대무독성용량은 2000 mg/kg 이상으로 간주되었다.